201 related articles for article (PubMed ID: 24272524)
1. Analysis of the cytotoxic effects of ruthenium-ketoconazole and ruthenium-clotrimazole complexes on cancer cells.
Robles-Escajeda E; Martínez A; Varela-Ramirez A; Sánchez-Delgado RA; Aguilera RJ
Cell Biol Toxicol; 2013 Dec; 29(6):431-43. PubMed ID: 24272524
[TBL] [Abstract][Full Text] [Related]
2. Tumor apoptosis induced by ruthenium(II)-ketoconazole is enhanced in nonsusceptible carcinoma by monoclonal antibody to EGF receptor.
Strasberg Rieber M; Anzellotti A; Sánchez-Delgado RA; Rieber M
Int J Cancer; 2004 Nov; 112(3):376-84. PubMed ID: 15382061
[TBL] [Abstract][Full Text] [Related]
3. Antifungal promising agents of zinc(II) and copper(II) derivatives based on azole drug.
de Azevedo-França JA; Borba-Santos LP; de Almeida Pimentel G; Franco CHJ; Souza C; de Almeida Celestino J; de Menezes EF; Dos Santos NP; Vieira EG; Ferreira AMDC; de Souza W; Rozental S; Navarro M
J Inorg Biochem; 2021 Jun; 219():111401. PubMed ID: 33756392
[TBL] [Abstract][Full Text] [Related]
4. Metal-drug synergy: new ruthenium(II) complexes of ketoconazole are highly active against Leishmania major and Trypanosoma cruzi and nontoxic to human or murine normal cells.
Iniguez E; Sánchez A; Vasquez MA; Martínez A; Olivas J; Sattler A; Sánchez-Delgado RA; Maldonado RA
J Biol Inorg Chem; 2013 Oct; 18(7):779-90. PubMed ID: 23881220
[TBL] [Abstract][Full Text] [Related]
5. Searching for new chemotherapies for tropical diseases: ruthenium-clotrimazole complexes display high in vitro activity against Leishmania major and Trypanosoma cruzi and low toxicity toward normal mammalian cells.
Martínez A; Carreon T; Iniguez E; Anzellotti A; Sánchez A; Tyan M; Sattler A; Herrera L; Maldonado RA; Sánchez-Delgado RA
J Med Chem; 2012 Apr; 55(8):3867-77. PubMed ID: 22448965
[TBL] [Abstract][Full Text] [Related]
6. Silver(I) complexes containing N-heterocyclic carbene azole drugs: Synthesis, characterization, cytotoxic activity, and their BSA interactions.
da Silva Dos Reis Condé CA; de Andrade Querino AL; Silva H; Navarro M
J Inorg Biochem; 2023 Sep; 246():112303. PubMed ID: 37413946
[TBL] [Abstract][Full Text] [Related]
7. Ruthenium-Clotrimazole complex has significant efficacy in the murine model of cutaneous leishmaniasis.
Iniguez E; Varela-Ramirez A; Martínez A; Torres CL; Sánchez-Delgado RA; Maldonado RA
Acta Trop; 2016 Dec; 164():402-410. PubMed ID: 27693373
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of transition metal derivatives of ketoconazole and clotrimazole against a wild type strain of Saccharomyces cerevisiae in absence or presence of human neutrophils.
Navarro M; Colmenares I; Correia H; Hernández A; Ching Y; Millán Y; Ojeda LE; Velásquez M; Fraile G
Arzneimittelforschung; 2004; 54(11):746-51. PubMed ID: 15612615
[TBL] [Abstract][Full Text] [Related]
9. Toward a novel metal-based chemotherapy against tropical diseases. 6. Synthesis and characterization of new copper(II) and gold(I) clotrimazole and ketoconazole complexes and evaluation of their activity against Trypanosoma cruzi.
Navarro M; Cisneros-Fajardo EJ; Lehmann T; Sánchez-Delgado RA; Atencio R; Silva P; Lira R; Urbina JA
Inorg Chem; 2001 Dec; 40(27):6879-84. PubMed ID: 11754267
[TBL] [Abstract][Full Text] [Related]
10. Synergistic Interaction of CPP2 Coupled with Thiazole Derivates Combined with Clotrimazole and Antineoplastic Drugs in Prostate and Colon Cancer Cell Lines.
Duarte D; Vale N
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769414
[TBL] [Abstract][Full Text] [Related]
11. Ru(II)/clotrimazole/diphenylphosphine/bipyridine complexes: Interaction with DNA, BSA and biological potential against tumor cell lines and Mycobacterium tuberculosis.
Colina-Vegas L; Dutra JL; Villarreal W; de A Neto JH; Cominetti MR; Pavan F; Navarro M; Batista AA
J Inorg Biochem; 2016 Sep; 162():135-145. PubMed ID: 27383651
[TBL] [Abstract][Full Text] [Related]
12. Anticancer activity of two novel ruthenium compounds in gastric cancer cells.
Ramírez-Rivera S; Pizarro S; Gallardo M; Gajardo F; Delgadillo A; De La Fuente-Ortega E; MacDonnell FM; Bernal G
Life Sci; 2018 Nov; 213():57-65. PubMed ID: 30326218
[TBL] [Abstract][Full Text] [Related]
13. On the Cytotoxicity of Chiral Ruthenium Complexes Containing Sulfur Amino Acids against Breast Tumor Cells (MDA-231 and MCF-7).
Leite CM; de Araujo-Neto JH; Corrêa RS; Colina-Vegas L; Martínez-Otero D; Martins PR; Silva CG; Batista AA
Anticancer Agents Med Chem; 2021; 21(9):1172-1182. PubMed ID: 32838726
[TBL] [Abstract][Full Text] [Related]
14. Heterobimetallic Ru(ii)/Fe(ii) complexes as potent anticancer agents against breast cancer cells, inducing apoptosis through multiple targets.
Guedes APM; Mello-Andrade F; Pires WC; de Sousa MAM; da Silva PFF; de Camargo MS; Gemeiner H; Amauri MA; Gomes Cardoso C; de Melo Reis PR; Silveira-Lacerda EP; Batista AA
Metallomics; 2020 Apr; 12(4):547-561. PubMed ID: 32108850
[TBL] [Abstract][Full Text] [Related]
15. Spectroscopic Study of the Interactions of Ruthenium-Ketoconazole Complexes of Known Antiparasitic Activity with Human Serum Albumin and Apotransferrin.
Estrada JG; Sánchez-Delgado RA
J Mex Chem Soc; 2013; 57(3):169-174. PubMed ID: 24391686
[TBL] [Abstract][Full Text] [Related]
16. Systematic evaluation of the antitumor activity of three ruthenium polypyridyl complexes.
Jiang GB; Zhang WY; He M; Gu YY; Bai L; Wang YJ; Yi QY; Du F
J Inorg Biochem; 2021 Dec; 225():111616. PubMed ID: 34555601
[TBL] [Abstract][Full Text] [Related]
17. Dimetallic Ru(II) arene complexes appended on bis-salicylaldimine induce cancer cell death and suppress invasion via p53-dependent signaling.
Rahman FU; Bhatti MZ; Ali A; Duong HQ; Zhang Y; Ji X; Lin Y; Wang H; Li ZT; Zhang DW
Eur J Med Chem; 2018 Sep; 157():1480-1490. PubMed ID: 30282320
[TBL] [Abstract][Full Text] [Related]
18. Light-activated ruthenium (II)-bicalutamide prodrugs for prostate cancer.
Zhao J; Liu N; Sun S; Gou S; Wang X; Wang Z; Li X; Zhang W
J Inorg Biochem; 2019 Jul; 196():110684. PubMed ID: 31054419
[TBL] [Abstract][Full Text] [Related]
19. Conjugation of a Ru(II) arene complex to neomycin or to guanidinoneomycin leads to compounds with differential cytotoxicities and accumulation between cancer and normal cells.
Grau-Campistany A; Massaguer A; Carrion-Salip D; Barragán F; Artigas G; López-Senín P; Moreno V; Marchán V
Mol Pharm; 2013 May; 10(5):1964-76. PubMed ID: 23510087
[TBL] [Abstract][Full Text] [Related]
20. Ruthenium (II) complexes with N, O-chelating proline and threonine ligands cause selective cytotoxicity by the induction of genomic instability, cell cycle arrest and apoptosis in breast and prostate tumor cells.
de Sousa IH; Campos VNS; Vale AAM; Maciel-Silva VL; Leite CM; Lopes AJO; Mourão PS; das Chagas Alves Lima F; Batista AA; de Azevedo Dos Santos APS; Almeida MAP; Pereira SRF
Toxicol In Vitro; 2020 Feb; 62():104679. PubMed ID: 31676337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
